Skip to main content
. 2008 Jul 7;155(3):291–299. doi: 10.1038/bjp.2008.284

Table 4.

Combination therapy with an ICSa and an ultra LABAb under development

  Pros Latest developments Who is working on this strategy
Carmoterol+budesonide It is twofold more effective than the formoterol/budesonide combination Preclinical phase Chiesi
Indacaterol+mometasone (QMF149) It has a superior delivery profile than formoterol/budesonide owing to its once-daily dosing Phase III Novartis
a

ICS, inhaled corticosteroid.

b

LABA, long-acting β-agonist.